Typhoid Conjugate (TCV)
Typhoid Conjugate Vaccine (Vi-TCV)
Platform: Vi-polysaccharide conjugate
Conjugate vaccine that protects against typhoid fever, a systemic bacterial infection caused by Salmonella Typhi.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗
Typhoid vaccines are vaccines that prevent typhoid fever. Several types are widely available: typhoid conjugate vaccine (TCV), Ty21a and Vi capsular polysaccharide vaccine (ViPS). Depending on the type, typhoid vaccines are estimated to be about 50% to 85% effective. The Vi-rEPA vaccine is efficacious in children.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗No Semantic Scholar results retrieved.